TARRYTOWN, N.Y., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the first presentation of positive two-year (96 weeks) results from the pivotal PULSAR trial investigating EYLEA ® HD (aflibercept) Injection 8 mg with 12- and 16-week dosing regimens, compared to EYLEA ® (aflibercept) Injection ...

EYLEA® (aflibercept) Injection 2 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR). Please click here for the full Prescribing Information for EYLEA HD and

The recommended dose for EYLEA is 2 mg (0.05 mL of 40 mg/mL solution) administered by intravitreal injection every 4 weeks (approximately every 28 days, monthly) for the first 5 injections followed by 2 mg (0.05 mL of 40 mg/mL solution) via intravitreal injection once every 8 weeks (2 months). (2.7, 2.8)

1 day ago · A higher-dose formulation of Eylea saw U.S. sales more than double Regeneron Pharmaceuticals Inc.'s stock rose 3% early Tuesday, after the company posted better-than-expected fourth-quarter ...

EYLEA® (aflibercept) & EYLEA® HD (aflibercept) Injections are FDA approved anti-VEGF treatments for Wet AMD, DME, and DR. See Important Safety Info and Full Prescribing Information.

Aflibercept, sold under the brand names Eylea and Zaltrap among others, is a medication used to treat wet macular degeneration and metastatic colorectal cancer. [16][17] It was developed by Regeneron Pharmaceuticals.

Apr 29, 2024 · EYLEA HD (known as Eylea™ 8 mg in the European Union and other ex-US countries) is being jointly developed by Regeneron and Bayer AG. In the U.S., Regeneron maintains exclusive rights to EYLEA HD and EYLEA.

5 days ago · Learn about Regeneron, the manufacturer behind Eylea, a groundbreaking treatment for retinal diseases. Discover the science and innovation driving this medication.

Aug 18, 2023 · The U.S. Food and Drug Administration approved a higher dose version of Regeneron Pharmaceuticals' drug Eylea for treatment of a disease that is a leading cause of blindness among the elderly,...

Regeneron Pharmaceuticals announced that the FDA has approved its Eylea injection treatment for wet age-related macular degeneration (AMD). The treatment, known in the scientific literature as VEGF Trap-Eye, was approved at a recommended dose of 2 mg every four weeks for the first twelve weeks, followed by 2 mg dose every two months (1 & 2).